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osteolytic or osteosclerotic bone lesions were detectable. HHV-8
DNA was no longer detectable in marrow or blood. The patient
received 4 cycles of idarubicine/dexamethasone. The response to
this treatment was minimal and an ASCT was planned. After
mobilisation chemotherapy with iphosphamide, epirubicine and
etoposide, 29.65 x 106 CD34-positive progenitor cells/kg could be
harvested with one leukapheresis. ASCT was performed after high
dose therapy with melphalan 200 mg/m2. Reinfusion of 14.83 
106 CD34-positive progenitor cells/kg and medication with G-
CSF resulted in engraftment on day 9. Restaging 5 weeks later
showed an excellent response. Bone marrow plasma cell inﬁltration
was no longer detectable and hypercellularity of megakaryopoesis
was markedly reduced. The platelet counts had returned to normal
and the pleural effusions had vanished. IgG and serum electro-
phoresis were normal while the immunoﬁxation remained positive
for IgG lamda. The polyneuropathy of the patient is continuously
improving. In conclusion, this case may represent an evolution
from possibly HHV-8 related POEMS syndrome to multiple my-
eloma. Despite lack of response to standard chemo- and immuno-
therapy ASCT seems to be a useful therapeutic option in patients
with signs of POEMS syndrome.
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Immunologic responses to the malignant plasma cells of multiple
myeloma (MM) patients are beinginvestigated for their ability to
prevent disease relapse after autologous and allogeneic haemato-
poietic stem cell transplantation. Dendritic cells (DC) are special-
ized leukocytes that have the capacity to prime and direct an
immune response against tumour-associated antigens (TAA). We
have used new Trucount® technology to evaluate the whole blood
DC subset composition of healthy donors and MM patients. MM
donors have similar numbers of CD11c CD16 and
CD11cCD16-blood DC subsets but about half the number of
CD11c-CD123 blood DC compared to normal donors. A
CMRF-56 monoclonal antibody-based immunomagnetic selection
procedure was used to enrich blood DC for functional studies from
the peripheral blood mononuclear cells of healthy donors and MM
patients. CMRF-56 blood DC from MM patients are efﬁciently
activated ex vivo and induce autologous and allogeneic mixed lym-
phocyte responses. The CMRF-56 blood DC preparation is able
to present MHC class I -restricted peptide antigens and has been
used to generate cytotoxic T lymphocytes (CTL) against MM
-related TAA, hTERT and MUC1. We have optimised the load-
ing of CMRF -56 blood DC preparations with antigen-encoding
mRNA and have shown that enhanced green ﬂuorescent protein
mRNA is rapidly transl ated after electroporation into blood DC.
In addition, inﬂuenza matrix protein (FMP) mRNA -loaded blood
DC can process and present antigen to FMP-speciﬁc CTL clones
and prime FMP-speciﬁc CTL responses in whole PBMC popula-
tions. We are currently in the process of generating responses
against total RNA extracted from MM cell lines prior to initiating
a clinical trial of RNA-loaded CMRF-56 blood DC in patients.
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FREELITE; A NEW LABORATORY TOOL TO AIDE IN MONITORING
MULTIPLE MYELOMA AFTER TREATMENT
Staggs, B., Fender, B., Joseph, L. University of Arkansas for Medical
Sciences, Little Rock, AR
Background: Multiple Myeloma (MM) is a diagnosis based on
multiple parameters. Immunoglobulin levels, radiography, and
bone marrow morphology are all evaluated for diagnosis and dis-
ease monitoring. Each test examines a different aspect of the
disease. Conﬂicting values between these can obscure the disease
picture. In addition, there are several subsets of MM depending on
the immunoglobulin secreted. However, one thing is common to
all but 5% of MM patients; an excess of free light chains is
produced. A new laboratory test, Freelite™, easily and accurately
measures free light chains in the serum. Methods: One hundred
ﬁfty patients with MM who had undergone treatment, some in-
cluding bone marrow transplant, were prospectively examined.
Fifty were patients treated for free light chain MM. Seventy-two
were patients treated for IgG MM and 28 were patients treated for
IgA secreting MM. The current serum free light chains were
examined using Freelite™ and then correlated to the disease state
as identiﬁed by consensus of bone marrow biopsy, ﬂow cytometry
and electrophoresis. Results: Thirty-seven of the 50 patients
treated for free light chain MM currently had disease. All 37 had
markedly elevated serum free light chain levels. The 13 remaining
patients were diagnosed “negative” or “atypical” and 8 of these had
elevated serum free light chain levels. Forty-six of 100 patients
treated for IgG or IgA MM currently had disease. All 46 of these
had elevated serum free light chain levels. Fifty-four were diag-
nosed “negative” or “atypical” and 30 had elevated serum free light
chain levels. Discussion: In this broad analysis of the most com-
mon subtypes of MM, Freelite™ is 100% sensitive when correlated
to MM diagnosed by our standard methods. The issue then be-
comes the decreased speciﬁcity (43%) due to false positives that are
seen in every subset. This may well be detection of recurrent or
residual disease not seen by our standard methods. Only close
follow-up will determine if these “false positive” patients recur
before the “true negative” patients. This sensitive and quick serum
analysis may prove to be an excellent tool for monitoring MM
patients after treatment.
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AUTOLOGOUS VERSUS ALLOGENEIC STEM CELL TRANSPLANT FOR
MULTIPLE MYELOMA
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We report results of a comparative analysis of 87 patients with
multiple myeloma, treated with either autologous PBSCT (n 70)
or allogeneic sibling donor myeloablative transplant (n 17) using
cyclophosphamide and fractionated TBI conditioning. Autologous
transplant recipients were signiﬁcantly older (median age 53 vs. 47
years, p  .01) and had a longer period between diagnosis and
transplant (10.5 vs 7 months, p .03). Autologous transplant led to
lower transplant related mortality (TRM) of 4% (95% CI 0-36%)
vs. 18% (0-9%) in the allogeneic patients at 100 days post trans-
plant (p  .02). More frequent complete responses (CR) were seen
in the allogeneic patients (64% (95%CI 37-91%) vs. 34% (95%CI
23-45%) in the autologous patients, p  .09). In the autologous
patients, overall survival of 86% (95% CI 80-95%) at one year and
50% (95% CI 47-75%) at 4 years was seen vs. 64% (95% CI
40-87%) at one year and at 4 years in the allogeneic patients. In
patients surviving beyond one year, survival was superior in the
allogeneic transplant patients (100% (95% CI 100-100%) versus
58% (95% CI 41-75%) at 4 years, p  .02). The cumulative
incidence of relapse showed a trend towards higher relapse in the
autologous patients (73% (95% CI 55-90%) versus (37% (95% CI
11-63%) in allogeneic patients at 4 years, p  .1). In multiple
regression analysis, attainment of a CR or PR pre transplant (OR
3.4, 95% CI 0.9-12.9, p  .06),  1 year between diagnosis and
transplant (OR 3.8, 95% CI 1.1-13.8, p  .04),  2 regimens of
chemotherapy (OR 8.3, 95% CI 2.2-31.3, p .01) were associated
with good response. Early transplant with 4 chemo cycles (RR of
failure 0.5 (95% CI 0.2-0.9, p  0.04) and attainment of CR or PR
post transplant (RR 0.4 (95% CI 0.2-0.7, p  0.01) was a signiﬁ-
cant predictor of good overall and progression free survival. Older
age at transplant (RR 1.1, 95% CI 0.9-1.3, p  .06), allogeneic
transplant (RR 11.0, 95% CI 2.3-53.7, p  .01), and  4 cycles of
pretransplant chemotherapy (RR 6.3, 95% CI 1.1-35.7, p  .04)
were each signiﬁcant predictors of high TRM. We observed good
clinical tolerance of the myeloablative conditioning regimen fol-
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